RIPK1 and rhabdomyosarcoma: Treatment of rhabdomyosarcoma cells with obatoclax (GX15-070), a small-molecule inhibitor of Bcl-2, stimulates ATG5 recruitment signals at the autophagosomal membrane, which serves as a platform where RIPK1, RIPK3 and FADD assembly mediates necrosis, but knockdown of RIPK1 does not inhibit autophagy (Fig. 4) [90].